Plain-English translation of NCT06260059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether Empagliflozin, a medication already approved by the FDA for heart failure, can help adults who were born with congenital heart disease. The medication works by reducing inflammation in the heart and protecting heart function. Researchers want to see if taking this medication every day for one year can prevent heart rhythm problems and heart muscle weakening before serious symptoms develop.
Many adults born with congenital heart disease develop heart failure and arrhythmias (irregular heartbeats) as they age, even after childhood surgery. Currently, doctors only start treatment after these serious problems appear, when significant heart damage has already occurred. This trial is testing whether the medication could work as a preventative treatment to protect the heart before damage happens.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to take either the active medication or a placebo (a pill that looks identical but contains no medicine) once daily for one year. Neither you nor the study team will know which group you're in. You will have regular clinic visits for heart imaging tests, blood work to check for inflammation, and computer-based thinking and memory assessments to track how the treatment affects your overall health.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States